A successful clinical trial requires many things, but perhaps the most resource-intensive element is the timely recruiting of an adequate number of suitable, reliable participants that meet the protocol guidelines. This is even more important when the trial needs to target patients with conditions or specific genetic backgrounds.
With the pandemic reducing the volume of international travelers that had previously formed a large portion of the participant pool, Nucleus Network pivoted to target other demographics to fill the participant cohorts for their clinical trials. Whilst not without its challenges in an unpredictable and unchartered market, Nucleus has proceeded with delivering recruitment volumes at rate equal to or exceeding the pre-COVID level.
In this webinar we will be discussing initiatives implemented in adapting to the “new norm,” as well as the outlook in Australia for healthy volunteer recruitment in a restricted market. Speakers from Nucleus Network will include CEO Cameron Johnson, Business Development Director Jeffrey Wong, and Communications Director Mari Ericksen.
Register for this webinar to hear about how:
- Australia is open for business for Phase 1 and scaling up medical research capacity
- With facilities in the USA and Australia, Nucleus Network can offer integrated, multi-site trial capability
- Interest in medical research is higher than ever in the general public and harnessing this for clinical trials requires a new approach
Cameron Johnson, CEO, Nucleus Network
One of Australia’s leading Phase 1 clinical trial professionals, Cameron Johnson joined Nucleus Network in 2013 as Chief Operating Officer before stepping into the role of CEO in 2016. Under his leadership, Nucleus Network has expanded with the acquisition of clinical sites in Brisbane and the US to become the only Australian Phase 1 clinical trial organization with a presence in both Australia and the US. Cameron’s extensive Phase 1 clinical trial experience includes positions as CEO and COO roles in interstate facilities.Message Presenter
Jeffrey Wong, Director of Business Development, Nucleus Network
As Director of Business Development, Jeffery Wong oversees Nucleus Network’s global business development team spanning both Australia and the USA and is responsible for Nucleus Network’s strategy for entering into new regions whilst consolidating existing markets. Jeffery has a background in pharmaceutical sciences, biotechnology, and business as well as more than 15 years of experience in project management and clinical development. Building on his extensive corporate knowledge, Jeffery is passionate in value adding early-stage engagement with prospective collaborators and to provide the most optimal solution towards their clinical development plan.Message Presenter
Mari Ericksen, Director of Marketing and Communications, Nucleus Network
Mari is responsible for leading and directing Nucleus Network’s Marketing team, developing, and executing integrated marketing strategic for both our participant markets in Brisbane, Melbourne and Minneapolis as well as our growing global pharmaceutical and biotech markets. With over 20 years’ experience in delivering results-driven marketing campaigns across the US, Europe and APAC, Mari has extensive experience in education and awareness campaigns, market research and data analysis, public relations, agency, and brand management. She is passionate about using data, strategic tactics and innovative marketing technologies to optimize and maximize engagement with core audiences.Message Presenter
Who Should Attend?
Anyone involved in the following sectors:
- Medical and Life Sciences
The webinar will appeal to a range of different functions, including CEO, CMO, CSO, COO, CFO, VP, and recruitment departments.
What You Will Learn
In this webinar, participants will learn:
- How Nucleus network pivoted from the familiar transient participant pool to a local population during a severe lockdown
- How the company was able to leverage the new profile of medical research and clinical trials to generate earned media coverage
- What strategies were implemented to rapidly retarget to a new audience
- Insight into the motivations of participants during this period, and how they are slightly different from those in the past
Nucleus Network is the only multi-site phase I clinical trials provider located in Australia and the USA. We provide high-quality, first-in-human, and early-phase trials for biotechnology and pharmaceutical companies across the USA, Europe and Asia. Located within cutting-edge health precincts, our cost-effective, accelerated clinical development solutions are supported by advanced technology, clinical excellence and research expertise.